Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
pharmaand GmbH
With
Foundation Medicine
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have histologically or cytologically confirmed locally advanced unresectable or metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter, urinary bladder or urethra)
Received 1 or 2 prior treatment regimens for advanced or metastatic disease
Confirmed radiologic disease progression during or following recent treatment
Mandatory biopsy is required during screening
Measurable disease per RECIST v1.1
Adequate organ function
ECOG 0 or 1
You may not be if
Prior treatment with a PARP inhibitor
Symptomatic and/or untreated CNS metastases
Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption of rucaparib
Clareo Health | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
